TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03244540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCA (patient controlled analgesia)
Description: All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCA (patient controlled analgesia)
Description: All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
Study: NCT01925066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Study: NCT00287989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 1500mg
Study: NCT04592237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study: NCT04554940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vosoritide
Description: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study: NCT02568267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor
Study: NCT01053377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamiflu (verum)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamiflu placebo
Study: NCT03186482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Descovy® (TAF/FTC)
Description: 25/200 mg once daily for 28 days (DAYS 1-28).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread® (TDF)
Description: 245 mg once daily for 28 days (DAYS 57-84).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifadin® (Rifampicin)
Description: 600 mg once daily for 28 days (DAYS 29-56).
Study: NCT06127576

Intervention type: DEVICE
Intervention: paraboloid geometry double and triple dental abutment-implant
Description: The implants were inserted with the margin between machined and micro-rough surface at bone level. The abutment and crowns were assembled and screw retained onto the implant with a torque of 35 Ncm.~The implants were cylindrical with internal hexagon and without surface treatment, presenting 4.0 mm in diameter and length varying between 10 and 13 mm.~Acording to the manual work model measurements, DA or TA acrylic individualized design and paraboloid surfaces of the DA (elliptical) and TA (hyperbolic) had been made.
Study: NCT02653638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Study: NCT03895489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Journey II
Description: Smith and Nephew Richards (SNR) Journey II Knee prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker
Description: Stryker Triathlon Total Knee prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer
Description: Zimmer Persona® The Personalized Knee prosthesis
Study: NCT03192644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI
Description: transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicin and cisplatin and lipiodol
Description: epidoxorubicin and cisplatin and lipiodol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Description: oxaliplatin, calcium folinate, and 5-FU
Study: NCT02290002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate
Description: 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coasting
Description: In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
Study: NCT03510624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebaudioside A
Description: Rebaudioside A 3g
Study: NCT04411979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment-as-usual plus aerobic walking
Description: aerobic walking
Study: NCT03510624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebaudioside A
Description: Rebaudioside A 3g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empty capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empty capsules
Study: NCT01125722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive neurostimulation device
Description: Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive neurostimulation device
Description: Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
Study: NCT01575743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercising
Description: All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercising
Description: All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
Study: NCT04064970

Intervention type: BEHAVIORAL
Intervention: patient acceptable symptom state (PASS)
Description: The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
Study: NCT03429244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET-MRI
Description: Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET-MRI
Description: Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET-MRI
Description: Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.
Study: NCT01134679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary disease management approach
Description: Follow up with phone calls
Study: NCT02012790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
Study: NCT03229928

Intervention type: DEVICE
Intervention: MOCHA
Description: * MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants).

Intervention type: DEVICE
Intervention: MOCHA
Description: * MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants).

Intervention type: DEVICE
Intervention: MOCHA
Description: * MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants).
Study: NCT05902091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurophysiology-based intervention
Study: NCT00893347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
Study: NCT04257032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin + BI 1323495
Description: Tablets
Study: NCT00893347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Description: 6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
Study: NCT00832195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion Controlling Running Shoe
Description: Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Running Shoe
Description: Standard running shoe with single density mid-sole foam.
Study: NCT02442843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
Study: NCT04257032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate + BI 1323495
Description: Capsule and tablets
Study: NCT03644823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PDL1- inhibitor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6 Gy x 3
Study: NCT00737295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CCK Injection and Ultrasound
Description: All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder.
Study: NCT00697190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric
Description: silicone hydrogel contact lens for patients with astigmatism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric
Description: silicone hydrogel contact lens for patients with astigmatism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A toric
Description: silicone hydrogel contact lens for patients with astigmatism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A toric
Description: silicone hydrogel contact lens for patients with astigmatism
Study: NCT01632943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity renal denervation system
Description: Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator.
Study: NCT04444518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAX-MOM Intervention
Description: The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard vaccine education and processes provided to patients by obstetric practices.
Study: NCT04079530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR 0.2 mg/day
Description: K-877 IR 0.1 mg tablet
Study: NCT03880968

Intervention type: DRUG
Intervention: tapering or discontinuation of etanercept
Description: Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).

Intervention type: DRUG
Intervention: tapering or discontinuation of etanercept
Description: Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).

Intervention type: DRUG
Intervention: tapering or discontinuation of etanercept
Description: Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).

Intervention type: DRUG
Intervention: tapering or discontinuation of etanercept
Description: Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).

Intervention type: DRUG
Intervention: tapering or discontinuation of etanercept
Description: Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
Study: NCT02694354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo